Selective or Systemic: Choosing the Pulmonary Vasodilator for a Failing Right Ventricle
A 59-year-old woman with longstanding pulmonary hypertension develops acute right heart failure after mitral valve surgery. The drug that most precisely targets her pulmonary vasculature isn't the only reasonable answer once her low cardiac output is added to the picture.
Diane K., a 59-year-old woman, was diagnosed with rheumatic mitral stenosis in her thirties after a childhood bout of rheumatic fever nobody had connected to her heart until she presented with atrial fibrillation and progressive dyspnea, and has lived for over two decades since with pulmonary hypertension that developed as a secondary consequence of years of elevated left atrial pressure transmitted backward through her pulmonary circulation. She remains in rate-controlled atrial fibrillation, longstanding rather than new, which means she has also spent those two decades without an atrial kick — a contribution her right ventricle has never been able to count on and will not suddenly acquire tonight.
Her mitral valve replacement today was technically successful, resecting the stenotic native valve and seating a bioprosthesis, but her right ventricle has spent two decades adapting to chronically elevated afterload, and adaptation is not the same thing as reserve. Coming off bypass, that ventricle is visibly dilated and hypokinetic on transesophageal echocardiography, with a pulmonary artery pressure still running roughly two-thirds of systemic despite the new valve having already relieved the upstream pressure that originally drove her pulmonary hypertension — years of vascular remodeling do not reverse the moment the inciting lesion is fixed. Her cardiac index is 2.0 L/min/m² — reduced, but reduced on the right side of the heart rather than the left, which is a different problem with a different set of answers. Her systemic blood pressure is holding but unimpressively, mean arterial pressure in the low 60s on a modest norepinephrine infusion. That last number narrows the team's options more than anything on the echo: whatever addresses her pulmonary circulation cannot come at the cost of a systemic pressure she is already only marginally maintaining, which excludes any agent that lowers resistance without regard for which circulation it lowers it in.
Choosing what treats the pulmonary side without costing the systemic side
Inhaled nitric oxide, starting now. It's inactivated the moment it crosses into her bloodstream, bound by hemoglobin before it can cause any systemic vasodilation — exactly what we need given her MAP is already only marginally holding on norepinephrine. It directly lowers pulmonary vascular resistance without touching her systemic pressure at all.
I don't disagree with the selectivity argument, but I'd start with inhaled epoprostenol instead — several comparative studies have found it roughly as effective as NO for lowering PVR in this exact setting, delivered through the ventilator circuit without the dedicated equipment NO requires, at a fraction of the cost.
I'd also push back gently on treating rebound risk as a reason to prefer NO — epoprostenol carries essentially the same rebound-pulmonary-hypertension risk on abrupt discontinuation that NO does. That's not a real differentiator between them, just a shared property of both drug classes worth remembering when either one is eventually weaned.
Before either of you starts an inhaled agent, I want us to name what her TEE is actually showing — it's not just elevated resistance, her RV is hypokinetic. Neither inhaled option touches contractility directly. If there's a real pump-failure component here, not just afterload, I'd add low-dose milrinone alongside whichever inhaled agent you choose, accepting the systemic vasodilation risk with norepinephrine support already running.
I'm not arguing against the inhaled selectivity logic — I actually think it's the right first move for the resistance component specifically. I just don't want us treating resistance and contractility as the same problem when her echo is telling us they might not be.
Agreed: inhaled nitric oxide started for the resistance component, low-dose milrinone added once RV hypokinesis was confirmed on TEE, norepinephrine titrated upward to protect systemic pressure against milrinone's added vasodilation.
Not agreed: whether inhaled epoprostenol should become the default first-line selective vasodilator at this institution going forward given its cost advantage and comparable efficacy, or whether the team's deeper familiarity with NO dosing and weaning justifies continuing to reach for it first. Left as an institutional practice-pattern question rather than resolved for today's patient specifically.